Navigation Links
Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
Date:1/13/2012

ts European region and has reimbursement plans and KOL engagement underway.

ABOUT DAVID VEITCHMr. Veitch joins Savient with over 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and Immunology.  Most recently he served as Senior Vice President of European Marketing & Brand Commercialization at Bristol Myers Squibb, where he was responsible for leading the brand commercial organization for Europe across all disease areas and generating sales of $4 to $5 billion.  Prior to that, Mr. Veitch spent ten years serving in a number of leadership positions at Bristol-Myers Squibb.  Before his time at Bristol, Mr. Veitch spent ten years in a variety of managerial roles at SmithKline Beecham Pharmaceuticals.  He received his Bachelor of Science degree from Bristol University in Bristol, England. 

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
6. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
8. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
9. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
10. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014 /PRNewswire/ ... announced that its subsidiary, Molecular Profiles Ltd., is set ... the annual CPhI/ICSE Worldwide event in Paris ... with the rapid development of both standard and complex ... platform, which incorporates the company,s existing formulation and analytical ...
(Date:10/1/2014)... 1, 2014  Varian Medical Systems (NYSE: ... for the fourth quarter of fiscal year 2014 following ... 2014.  The news release will be followed by a ... PT.  The news release and a link to the ... website at: www.varian.com/investor .  To access the teleconference ...
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4
(Date:10/2/2014)... Philadelphia, PA (PRWEB) October 02, 2014 ... winners of the 2014 BIG Awards for Business ... companies and organizations with a proprietary judging process ... from around the globe. , “The winners this ... said Russ Fordyce, Managing Director of the Business ...
(Date:10/2/2014)... Salamon HealthDay Reporter ... with a neurotic personality style and prolonged stress may ... research suggests. Tracking 800 women over nearly four ... anxious, jealous and moody -- which they defined as ... risk of developing Alzheimer,s compared to women scoring lowest ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... and British scientists have now found that it is helpful in ... warfare. , ... Manhasset, NY (Vocus) May 6, 2009 ... found that it is helpful in delaying the effects of ricin, ...
... May 6 Parishioners at Guardian Angels Catholic Church in ... shelf -- they actually grow it themselves. The project is ... by the Institute for Agriculture and Trade Policy (IATP) and ... Cross) that demonstrate a growing nationwide movement within the faith ...
... 6 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that Brian ... Hite, Senior Vice President and Chief Financial Officer, are scheduled ... 2009 Healthcare Conference at the Palace Hotel in New York ...
... Mich., May 6 Perrigo Company (Nasdaq: ... Directors declared a quarterly dividend of $0.055 per share, ... on May 29, 2009. Perrigo Company is a leading ... (OTC) and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
... PA, 6 May 2009 Obstructive sleep apnea (OSA) ... in heart failure (HF) patients managed with beta-blockers and ... Journal of Cardiac Failure ( http://www.elsevier.com/locate/cardfail ), ... of Sleep Apnea in Patients with Heart Failure and ...
... lack of guidance and training provided for nurses involved in ... , Writing in the May issue of the Journal ... highlighted the need for an audit of current UK services ... , But they point out that the basic issues they ...
Cached Medicine News:Health News:Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 3Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 4Health News:Symmetry Medical to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference 2Health News:Sleep apnea may not be closely linked to heart failure severity 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: